一种对TME有反应性,自供氧的杂交聚合体,用于低氧瘤的协同三模疗法和精密治疗术
Zhe Tang1, Wanru Luo1, Mengmeng Xu1
1South China Advanced Institute for Soft Matter Science and Technology, School of Emergent Soft Matter, Guangdong Provincial Key Laboratory of Functional and Intelligent Hybrid Materials and Devices, Guangdong Basic Research Center of Excellence for Energy and Information Polymer Materials, South China University of Technology, Guangzhou 510640, China. yuqianqian@scut.edu.cn.
这项研究引入了一种新型纳米药物,可以对抗瘤缺氧,增强癌症治疗. 该系统提供了光动力学,化学动力学和化疗的组合,提高了疗效,并使精确瘤学的双模成像成为可能.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 瘤缺氧显著限制光动力疗法 (PDT) 和化疗的有效性.
- 开发克服瘤缺氧的策略对于改善癌症治疗结果至关重要.
研究的目的:
- 开发一种基于聚合体的新型纳米药物 (IR808/DOX@Psome/MnO2) 用于缓解瘤缺氧.
- 为了实现三种模式的治疗方法 (PDT,化学动力学疗法,化疗),结合双模式成像,用于精确的癌症治疗.
主要方法:
- 使用一个聚合体系统封装IR808和多克索鲁比 (DOX),与二氧化 (MnO2) 纳米酶.
- 瘤微环境 (TME) 激活了MnO2纳米酶,产生氧 (O2) 和基 (•OH).
- 评估了协同治疗效果和双模式成像 (MRI和光) 能力.
主要成果:
- 该纳米药物通过将过氧化 (H2O2) 转化为O2.2,成功降低了瘤缺氧.
- 通过OH生成和改善PDT疗效,实现了增强化学动力学疗法 (CDT).
- 通过抑制药物排泄,证明了同步的三种模式治疗和逆转化疗耐药性.
- 通过MRI和光成像实现了瘤向和治疗反应的实时可视化.
结论:
- IR808/DOX@Psome/MnO2系统为克服瘤缺氧和增强癌症治疗提供了一个有希望的策略.
- 该平台的模块化设计允许定制,这表明它在与缺氧有关的疾病中具有广泛的适用性.
- 这种综合治疗和成像方法代表了精密瘤学的重大进步.
更多相关视频
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
07:07Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance
Published on: February 14, 2025
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
